A new retrospective study on hydroxychloroquine has been posted (preprint) Similar to the VA study except it shows success not failure. This new study used HCQ only, no azithromycin or zinc was used.
A retrospective look at 568 patients in Wuhan. All of them were confirmed positive and on mechanical ventilation, median age 68, 63% male. 520 of them had standard of care (various antivirals and antibiotics), and in addition 48 patients were treated with 200mg hydroxychloroquine (b.i.d.) They measured hospital stay, mortality, and IL-6 levels as well. And their results were quite striking: mortality was 18.8% in the HCQ group and 45.8% in the others. Patient IL-6 levels declined significantly in the treatment group, but not in the other cohort. The preprint’s Figure 3 also indicates that IL-6 went back up after hydroxychloroquine was discontinued.
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 | medRxiv